Navigation Links
LTCPA Study Quantifying Unused Medicare Part D Drugs in Skilled Nursing Facilities Published in The Consultant Pharmacist

WASHINGTON, Sept. 7, 2011 /PRNewswire-USNewswire/ -- The Long Term Care Pharmacy Alliance's (LTCPA) recent study, "Measurement of Unused Medication in Medicare D Residents in Skilled Nursing Facilities," has been published in the September 2011 issue of The Consultant Pharmacist, the official peer-reviewed journal of the American Society of Consultant Pharmacists. This is the first published, peer-reviewed study to measure the quantity and the value of unused solid oral dosage from prescription drugs among Medicare Part D–covered residents in skilled nursing facilities.  The study was based upon actual dispensed and returned prescription data provided to the authors by long-term care pharmacies, and its data and methodology have undergone a rigorous peer-review.  

The study highlights several important findings:

  • The cost of unused Part D drug products dispensed to skilled nursing facility residents that could feasibly be reduced to shorter fill times – identified as brand and generic oral solid prescriptions – amounts to about 2.9% of total dispensed value of all prescriptions, or $125 million annually.
  • Based on the value of the unused drugs, moving to shorter fills via "short cycle dispensing" will very likely result in higher costs to the Medicare program. Shorter fills will result in more dispensed prescriptions and more dispensing fees charged to Medicare Part D prescription plans, overwhelming any potential savings.

The study, conducted by Managed Solutions, LLC and originally released by LTCPA in January 2011, supports pharmacists' contention that the "short cycle dispensing" provision inserted within the Patient Protection and Affordable Care Act (PPACA) is likely to create greater health care costs rather than savings. The intent of the provision was to reduce costs associated with medications unused by Part D-covered skilled nursing facility residents by moving from traditional 30-day fills to shorter fill times such as biweekly, weekly or daily. Debate has circulated around this provision and subsequent rule-making, as robust data quantifying the amount and costs associated with unused pharmaceuticals in the long term care space were not available. The study fills this gap in data and demonstrates that the costs associated with increasing the number of monthly dispensings are likely to outweigh any cost savings from reducing unused drugs.

To read the published study, click here.

The Long Term Care Pharmacy Alliance (LTCPA) advocates for the interests of the long term care (LTC) pharmacy community - a community that provides a critical component to the daily care of individuals living in LTC settings. LTCPA provides a national, unified voice on major issues including LTC pharmacy costs, specialized nursing facility pharmacy services and the Medicare Part D prescription drug benefit.  LTCPA membership is comprised of three national LTC pharmacy providers, Managed Health Care Associates (MHA), Omnicare and PharMerica that together serve 1.8 million Medicare Part D beneficiaries, or ninety percent of all LTC facility residents.

SOURCE Long Term Care Pharmacy Alliance (LTCPA)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Long Term Care Pharmacy Alliance Concerned with Proposed CMS Rule; New Study Confirms LTCPA Position
2. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
3. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Todays Competitive Healthcare Market
6. Study Explores Utilization Trends for Prostate Cancer Treatments
7. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
8. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
9. New Study Shows Modified Citrus Pectin Activates Powerful Immune Responses
10. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
11. Comparative Study Confirms Enox Biopharmas Antimicrobial Superiority to Commercially Available Silver Coated Catheters
Post Your Comments:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):